研究紹介(論文)

Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08

Masuishi T, Tsuji A, Kotaka M, Nakamura M, Kochi M, Takagane A, Shimada K, Denda T, Segawa Y, Tanioka H, Hara H, Sagawa T, Watanabe T, Takahashi T, Negoro Y, Manaka D, Fujita H, Suto T, Takeuchi M, Ichikawa W, Fujii M.

Br J Cancer. 2020 Aug 31. doi: 10.1038/s41416-020-01042-w. PMID: 32863385